News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Superbug Researchers Wait On Future Of AstraZeneca PLC (AZN) Drugs


5/23/2014 8:10:19 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AstraZeneca Plc (AZN) has some of the most promising experimental antibiotics in development. Even so, it’s thinking of exiting the business. Chief Executive Officer Pascal Soriot is considering all options for the medicines, including finding more experienced partners to develop them or selling them outright, he said in a telephone interview last week. Soriot is choosing to focus AstraZeneca’s resources on three broad areas where the company is strongest: cancer; heart disease and diabetes; and respiratory, inflammation and immune-system disorders.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg

comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES